Health care providers should not use non-invasive prenatal screening tests alone to diagnose genetic abnormalities due to the potential for false results, the Food and Drug Administration warned last week. Also known as cell-free DNA tests or non-invasive prenatal tests, these laboratory developed tests in most cases are not reviewed by the FDA.

“Patients and health care providers should be aware of the risks and limitations of using these genetic prenatal screening tests and that they should not be used alone to diagnose chromosomal (genetic) abnormalities,” FDA said, citing reports that some patients and providers have made critical health care decisions based on the results without additional confirmatory testing. 

Related News Articles

Headline
In this conversation, Terry Scoggin, CEO of Titus Regional Medical Center, discusses how the organization designed a system of care to ensure that every…
Headline
In this AHA blog Aisha Syeda, senior program manager for AHA’s Strategic Initiatives, summarizes five action steps hospitals can take to establish pediatric…
Blog
In 2024, the U.S. suffered 24 weather and climate disasters. In October alone, two major hurricanes devastated communities in North Carolina and Florida,…
Headline
In this “Safety Speaks” conversation, CommonSpirit Health's Beth Miller, system director, patient safety-performance improvement, and Austin Peterson, system…
Headline
In this conversation, Oren Guttman, M.D., anesthesiologist and vice president of High Reliability & Patient Safety at Thomas Jefferson University,…
Headline
In this conversation, Jennifer Richards, Ph.D., assistant professor at the Center for Indigenous Health, Johns Hopkins Bloomberg School of Public Health, and…